-+ 0.00%
-+ 0.00%
-+ 0.00%

Amdocs (DOX) Is Back In Focus, What Is Driving Attention Now?

Simply Wall St·11/21/2026 02:10:26
Listen to the news

Fresche Solutions’ new partnership with Amdocs (NasdaqGS:DOX) has pushed the stock into focus, as investors weigh how expanded IBM i and IBM z modernization services could influence sentiment around the business.

Amdocs has been under pressure for much of 2026, with the share price down 33.2% over the past month and 48.6% year to date, while the 1 year total shareholder return has declined 43.9%. The Fresche announcement therefore comes against a backdrop of weak momentum and a market that has been rethinking both the growth opportunity and perceived risk around the business.

Compare how Amdocs stacks up against other software players under pressure by scanning the hand-picked 41 high quality undervalued stocks that share a mix of quality, cash generation, and beaten-down sentiment.

Amdocs still runs a sizeable, cash-generating software operation, yet the share price reset and fresh IBM modernization tie-up pull the focus to a different issue: Are investors now overreacting or still paying too much?

Most Popular Narrative: 33% Undervalued

Amdocs last closed at $41.18, while the most followed narrative on Simply Wall St assigns a fair value of $61.79 using a discounted cash flow approach with a 9.05% discount rate. According to HarishPK, an investor in the Simply Wall St Community who built that framework, the Fresche deal now sits inside a much bigger question about how durable the franchise really is under pressure.

My revised DCF now assumes approximately 17% revenue contraction in the first forecast year, followed by only 3% annual growth through years 2-5. It produces an estimated value of approximately US$61.79 per share, substantially below my previous US$82.03 estimate. My earlier published narrative had estimated fair value at US$82.03 when the shares traded at US$62.43.

See why 42 investors see Amdocs as 33% undervalued.

Result: Fair Value of $61.79 (UNDERVALUED)

Still, the narrative around Amdocs could unravel further if revenue contraction persists beyond the initial hit, or if AI driven projects fail to convert into material contracts.

Find out about the key risks to this Amdocs narrative.

Next Steps

Sentiment around Amdocs is clearly split. This is exactly when it helps to move fast and test the numbers against your own framework using the 4 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Amdocs?

If Amdocs has your attention, do not stop here. The market is moving, and fresh ideas can slip by quietly when you only watch one ticker.